These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16268966)

  • 1. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study.
    Lu WZ; Gwee KA; Moochhalla S; Ho KY
    Aliment Pharmacol Ther; 2005 Nov; 22(10):927-34. PubMed ID: 16268966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary study of melatonin in irritable bowel syndrome.
    Saha L; Malhotra S; Rana S; Bhasin D; Pandhi P
    J Clin Gastroenterol; 2007 Jan; 41(1):29-32. PubMed ID: 17198061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
    Chang FY; Lu CL; Chen CY; Luo JC
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS.
    Jerndal P; Ringström G; Agerforz P; Karpefors M; Akkermans LM; Bayati A; Simrén M
    Neurogastroenterol Motil; 2010 Jun; 22(6):646-e179. PubMed ID: 20367800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
    Tack JF; Miner PB; Fischer L; Harris MS
    Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients.
    Mikocka-Walus A; Turnbull D; Moulding N; Wilson I; Andrews JM; Holtmann G
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1137-43. PubMed ID: 18070012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.
    Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D
    Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial.
    Pace F; Maurano A; Ciacci C; Savarino V; Attili A; Iaquinto G; Magni E; Porro GB
    Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):155-62. PubMed ID: 20391952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome.
    Saito YA; Rey E; Almazar-Elder AE; Harmsen WS; Zinsmeister AR; Locke GR; Talley NJ
    Am J Gastroenterol; 2010 Jan; 105(1):170-7. PubMed ID: 19809408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study.
    Bittner AC; Croffut RM; Stranahan MC
    Clin Ther; 2005 Jun; 27(6):755-61. PubMed ID: 16117982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial.
    Leung WK; Wu JC; Liang SM; Chan LS; Chan FK; Xie H; Fung SS; Hui AJ; Wong VW; Che CT; Sung JJ
    Am J Gastroenterol; 2006 Jul; 101(7):1574-80. PubMed ID: 16863563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No difference in symptoms of irritable bowel syndrome between healthy subjects and patients with recurrent depression in remission.
    Karling P; Danielsson A; Adolfsson R; Norrback KF
    Neurogastroenterol Motil; 2007 Nov; 19(11):896-904. PubMed ID: 17973640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome.
    Piche T; Ducrotté P; Sabate JM; Coffin B; Zerbib F; Dapoigny M; Hua M; Marine-Barjoan E; Dainese R; Hébuterne X
    Neurogastroenterol Motil; 2010 Jun; 22(6):626-e174. PubMed ID: 20403099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC; Barghout V; McBurney CR; Niecko TE
    Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.
    Wittmann T; Paradowski L; Ducrotté P; Bueno L; Andro Delestrain MC
    Aliment Pharmacol Ther; 2010 Mar; 31(6):615-24. PubMed ID: 20003095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.
    Clavé P; Acalovschi M; Triantafillidis JK; Uspensky YP; Kalayci C; Shee V; Tack J;
    Aliment Pharmacol Ther; 2011 Aug; 34(4):432-42. PubMed ID: 21679214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.